BioNTech/Pfizer published a press release regarding 94% efficacy in November 2020 (1 month before publishing any study) and it too landed on the front page:
Completely different - They are a large company with a proven track record and a lot to lose if they incorrectly claim efficacy. They were reporting on the results of a registered clinical trial with 30,000 subjects.
This shows results for ~ 48 transgenic mice. I would say that, at the time, the vaccine reported in the press release from Pfizer had a 99% chance of being approved by FDA, while this vaccine has maybe a 10% chance of being approved by the FDA at best.
You’re right, they completely differ from each other (regarding their relevance) and should therefore face an adjusted amount of scrutiny.
If you’re one of the top pharmaceutical companies in the world, some press releases and study protocols are simply not enough [1] and should be (imo) discarded.
If you’re a new player (Vaxxas) claiming “complete protection” by testing your product on mice, it’s simply not enough and should be (imo) discarded.
This shows results for ~ 48 transgenic mice. I would say that, at the time, the vaccine reported in the press release from Pfizer had a 99% chance of being approved by FDA, while this vaccine has maybe a 10% chance of being approved by the FDA at best.